SIMILAR MEAN FOLLITROPIN DELTA DAILY/TOTAL DOSES YIELD SATISFACTORY ICSI OUTCOMES IN DIFFERENT SUBGROUPS OF MATERNAL AGE AND BODY MASS INDEX: A "REAL-WORLD" EXPERIENCE WITH REKOVELLE

Edson Borges Jr. [1], Amanda Setti[1,2], Daniela Braga[1,2], Patricia Guilherme[1], Assumpto Iaconelli Jr[1,2].

[1] Fertility Medical Group [2] Instituto Sapientiae - Centro de Estudos e Pesquisa em Reprodução Assistida

P-590

INTRODUCTION

Rekovelle® (follitropin delta) is a novel recombinant human FSH (rFSH) expressed from a host cell line of human fetal retinal origin (PER.C6®) and is the first commercially available rFSH product derived from human cell lines. Rekovelle® allows the individualization of the initial dose of gonadotropin using predictive response factors to COS, such as anti-müllerian hormone (AMH) levels and body weight. In clinical practice different approaches can be adopted to obtain the most satisfactory response to controlled ovarian stimulation (COS). The objective of this study was to describe data on "real-world" Rekovelle® administration, regarding the response to COS and ICSI outcomes, and detecting whether similar mean follitropin delta daily/total doses can yield satisfactory ICSI outcomes in different subgroups of maternal age and body mass index (BMI).

METHODS

Jan 2018 — Dec 2022

- ✓ Non-interventional study based on secondary use of data
- ✓ Patients undergoing ICSI treatment in a private university-affiliated IVF center
- ✓ Pre-menopausal women
- ✓ COS with Rekovelle® (16 ug) daily;
- ✓ Fresh sperm from partner ejaculation;
- ✓ Presenting with both ovaries.

- ✓ Ovarian response to stimulation and ICSI outcomes were described for 362 ICSI cycles.
- ✓ Primary outcome: numbers of retrieved oocytes and maturity rates
- ✓ Secondary outcome: ongoing pregnancy rates per fresh and per fresh and/or frozen-thawed embryo transfer.
- ✓ The results obtained with the population enrolled in the ESTHER-1 trial (extern), and a population stimulated with follitropin alpha 300 IU (on site) were recorded (data not shown, to be presented).

RESULTS

Description of response to COS and ICSI laboratory outcomes among different subgroups of female BMI in Follitropin delta patients.



Description of response to COS and ICSI laboratory outcomes among different subgroups of female age in Follitropin delta patients.



CONCLUSIONS

Rekovelle® (follitropin delta) is a novel recombinant human FSH (rFSH) expressed from a host cell line of human fetal retinal origin (PER.C6®), and is the first commercially available rFSH product derived from human cell lines. Rekovelle® allows the individualization of the initial dose of gonadotropin using predictive response factors to COS, such as anti-müllerian hormone (AMH) levels and body weight. In clinical practice different approaches can be adopted to obtain the most satisfactory response to controlled ovarian stimulation (COS). The objective of this study was to describe data on "real-world" Rekovelle® administration, regarding the response to COS and ICSI outcomes, and detecting whether similar mean follitropin delta daily/total doses can yield satisfactory ICSI outcomes in different subgroups of maternal age and body mass index (BMI).